** Shares of Apellis Pharmaceuticals APLS.O rise 7.7% to $28.01 premarket, set to snap six-day losing streak
** Drugmaker's Q4 revenue of $212.5 mln beats Wall Street estimates of $198.4 mln - LSEG
** Q4 net loss $36.4 mln, narrower than $88.6 mln a year ago
** APLS fell 46.7% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。